Single dose of medical LSD shows promise in reducing anxiety
About 4% of the global population lives with an anxiety disorder, such as generalized anxiety disorder (GAD). While there are currently treatment options available for GAD, past studies show that about 50% of people will not respond to first-line treatments like antidepressant therapy. A new study reports the results of a phase 2b clinical trial of an LSD medication that shows promise in treating anxiety. The drug, called MM120, is an oral pharmaceutical form of LSD, the hallucinogenic drug also known as acid.